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Abstract
Myelodysplastic syndromes (MDS) are clonal stem cell disorders which frequently show a hypercellular dysplastic bone
marrow (BM) associated with inefficient hematopoiesis and peripheral cytopenias due to increased apoptosis and
maturation blockades. Currently, little is known about the role of cell proliferation in compensating for the BM failure
syndrome and in determining patient outcome. Here, we analyzed the proliferation index (PI) of different compartments of
BM hematopoietic cells in 106 MDS patients compared to both normal/reactive BM (n = 94) and acute myeloid leukemia
(AML; n = 30 cases) using multiparameter flow cytometry. Our results show abnormally increased overall BM proliferation
profiles in MDS which significantly differ between early/low-risk and advanced/high-risk cases. Early/low-risk patients
showed increased proliferation of non-lymphoid CD34+ precursors, maturing neutrophils and nucleated red blood cells
(NRBC), while the PI of these compartments of BM precursors progressively fell below normal values towards AML levels in
advanced/high-risk MDS. Decreased proliferation of non-lymphoid CD34+ and NRBC precursors was significantly associated
with adverse disease features, shorter overall survival (OS) and transformation to AML, both in the whole series and when
low- and high-risk MDS patients were separately considered, the PI of NRBC emerging as the most powerful independent
predictor for OS and progression to AML. In conclusion, assessment of the PI of NRBC, and potentially also of other
compartments of BM precursors (e.g.: myeloid CD34+ HPC), could significantly contribute to a better management of MDS.
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Introduction
Myelodysplastic syndromes (MDS) are heterogeneous clonal
stem cell disorders characterized by dysplastic hematopoiesis
leading to bone marrow (BM) failure and an increased risk of
transformation into acute myeloid leukemia (AML). Typically, the
disease is associated with impaired maturation and defective
production of myeloid cells, which translates into dysplastic
features, cytopenias and a remarkable negative impact on patient
survival [1]. Current prognostic stratification of MDS is mainly
based on the percentage of BM blast cells, the number of
cytopenias and cytogenetics [2], together with hemoglobin levels
and/or other more dynamic variables (e.g.: transfusion depen-
dency) [1,3]. However, currently used prognostic models based on
these variables remain relatively limited, particularly for predicting
the outcome of low risk MDS. Consequently, the search for
additional prognostic factors allowing for more precise prognostic
stratification and treatment selection of these patients remains a
challenge. Other parameters such as a poor performance status
together with an older age, leukocytosis, increased LDH serum
levels and the number and severity of comorbidities [4,5] have also
been associated with a poor outcome in low-risk MDS, but their
contribution to the prognostic models proposed so far still shows
important limitations, as discussed elsewhere [6,7].
The proliferation index (PI) of specific compartments of BM
cells is a dynamic parameter that reflects the ongoing rate of
production of hematopoietic cells in MDS, which can be easily
assessed at any time during the course of the disease [8]. In
addition, the PI is also directly related to the maturation-associated
alterations of distinct subtypes of hematopoietic cells in individual
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patients [8]. In this regard, early studies already showed epigenetic
repression of specific genes involved in the cell cycle and decreased
numbers of S-phase cells in association with BM failure among
advanced MDS and AML patients [9,10,11,12,13,14], suggesting
that assessment of the PI of BM cells in MDS may be of potential
relevance for prognostic stratification and monitoring of the
disease [15]. Despite this, information currently available about
the PI of BM cells in MDS remains very limited and controversial,
preliminary data in the literature suggesting that disease progres-
sion could be associated with both proliferation arrest and
enhanced expansion of clonal cells [9,14,16,17,18]. However,
careful analysis of these studies shows that many of them have
focused on the assessment of the proliferation rate of the overall
BM cellularity, which largely depends on the relative composition
of the sample in distinct cell compartments; moreover, these
studies are restricted to the analysis of a few BM cell compartments
in relatively small and unstratified cohorts of MDS patients,
without investigating its potential impact on the outcome of the
disease [9,11,19].
In this study, we analyzed for the first time the cell cycle
distribution of different compartments of BM hematopoietic cells –
e.g.: CD34+ hematopoietic progenitor and precursor cells,
maturing neutrophils and monocytic cells, mature lymphocytes,
eosinophils and nucleated red blood cell precursors (NRBC)- in a
relatively large cohort of 230 BM samples including 106 MDS
patients, 30 AML and 94 normal/reactive BM samples. Overall,
our results show altered BM proliferation profiles in MDS, which
significantly differ in early/low-risk vs. advanced/high-risk sub-
types of the disease: increased proliferation of myeloid CD34+
precursors, maturing neutrophils and NRBC in early phases of the
disease, and progressively decreased PI in advanced MDS and
AML. Noteworthy, a higher PI of non-lymphoid CD34+ cells and
NRBC were both associated with a significantly longer overall
survival (OS) and decreased risk of AML transformation, even
among patients within the low and intermediate-1 IPSS risk
categories, the PI of NRBC emerging as the most powerful
prognostic factor for both OS and progression-free survival in
MDS, independently of the haemoglobin levels and other classical
prognostic variables.
Materials and Methods
Bone Marrow Samples
A total of 136 untreated patients (78 men and 58 women; mean
age of 73 years, ranging from 38 to 87 years) with newly diagnosed
MDS (n = 106) and AML not otherwise specified (NOS; n = 30),
were included in the present study. According to the World Health
Organization (WHO) criteria [20], MDS patients were classified
as follows: RA, 7 patients; RA with ringed sideroblasts (-RS), 3;
RCMD, 31; RCMD-RS, 7; RAEB-1, 20; RAEB-2, 30; myelo-
dysplastic/myeloproliferative neoplasms (MD/MPN), 8 cases.
According to the International Prognostic Scoring System (IPSS)
[2], 25% of cases were classified as low-risk MDS, 41% as
intermediate-1, 18% as intermediate-2 and 16% as high-risk
MDS. Distribution of AML NOS cases, according to the WHO
2008 was as follows: AML with minimal differentiation, 3 patients;
AML without maturation, 4; AML with maturation, 8; AML with
myelodysplasia-related changes, 6; AML with myelomonocytic/
monocytic maturation, 5. The other 4 cases were classified as
mixed phenotype AL (T/myeloid, NOS). For multiparameter flow
cytometry immunophenotypic studies, EDTA-anticoagulated BM
samples were obtained at diagnosis from all MDS and AML cases.
Moreover, an additional validation cohort of 11 MDS patients was
analyzed both at diagnosis and at the last follow-up BM (mean
follow-up time of 1169 months; range: 4 to 36 months). Five of
these 11 patients (RCMD, 3; RAEB-1, 1; RAEB-2, 1) had the
same WHO diagnostic subtype at diagnosis and follow-up, while 4
(RCMD, 2; RAEB-1, 1; RAEB-2, 1) presented with more
advanced disease than at diagnosis (AML, RAEB-1, AML and
AML respectively). The remaining two patients (RCMD, 1;
RAEB-1, 1) were studied both at diagnosis and after treatment
when they had achieved morphological and cytogenetic remission
at the time of follow-up.
In parallel, 94 freshly obtained EDTA-anticoagulated normal
(n = 47) and reactive (n = 47) BM samples from an identical
Table 1. Proliferation index (percentage of S+G2M cells) of different BM cell compartments in MDS vs. both AML and normal/
reactive BM.
BM cell compartment Proliferation index of BM cell populations
Normal/reactive BM
(N=94) P-value{ MDS (N=106) P-value¥ AML (N=30) P-value*
Whole BM 7% (1–17.5%) ,0.001 9% (2–27%) 0.008 7% (0.3–17%) NS
Non-lymphoid CD34+ precursors 15% (6–28%) 0.05 13% (0.6–36%) ,0.001 6% (0.07–19%) ,0.001
Maturing neutrophils 5% (0.5–12%) ,0.001 7% (2–26%) NS 7% (0.3–17%) 0.02
CD13hi/CD11b2 cells 21% (4–37%) 0.01 19% (6–51%) NS 17.5% (2–54%) NS
CD13lo/int/CD11b2 cells 21% (12–36%) NS 21% (5–46%) NS 17% (3–41%) NS
CD13lo/int/CD11b+ cells 4 (0.8–12%) 0.002 5% (1–23%) NS 7% (1–43%) 0.001
CD13hi/CD11b+ cells 0.5% (0.1–4%) ,0.001 2% (0.3–12%) 0.007 2% (0.2–36%) ,0.001
Monocytic cells 4.5% (0.1–21%) NS 4% (0–16%) NS 7% (0–10%) NS
Nucleated red blood cell precursors 28% (11–45%) NS 26% (2–48%) 0.01 21% (2–37%) ,0.001
Eosinophils 4% (0–13%) 0.01 7% (0–21%) NS 5.5% (1.5–16%) NS
Results expressed as median percentage of S+G2/M cells and range between brackets. AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; BM, bone
marrow; NS, statistically not significantly different;
{, MDS vs. normal/reactive BM;
¥, MDS vs. AML;
*, AML vs. normal/reactive BM.
doi:10.1371/journal.pone.0044321.t001
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number of individuals (46 men and 48 women; mean age of 67
years; range, 47 to 79 years) were collected at the University
Hospital of Salamanca (Spain). Normal BM samples were
obtained from healthy donors and individuals undergoing
orthopedic surgery, while reactive samples corresponded to
patients with carential and megaloblastic anemias and other toxic
(e.g.: drug-induced) or reactive cytopenias, including infection-
associated leukopenias. None of the reactive samples showed
clonal hematopoiesis, based on the absence of cytogenetic
abnormalities –e.g., trisomy 8, 27/7q2, 25/5q2, del(20q) or
2Y- as assessed by fluorescence in situ hybridization (FISH) and/
or a polyclonal pattern of inactivation of chromosome X in
females, evaluated by the human androgen receptor assay
(HUMARA) in FACS-purified ($97% purity) maturing neutro-
phils, monocytic cells, NRBC, CD34+ hematopoietic progenitor
and precursor cells (HPC) and mature lymphocytes.
All BM samples were systematically studied within the first 18
hours after they were drawn, after written informed consent was
given by each subject according to the recommendations of the
local Ethics Committee -Comisio´n de Bioe´tica of Centro de
Investigacio´n del Ca´ncer-IBMCC (USAL-CSIC)-, which ap-
proved the study, and to the principles expressed in the
Declaration of Helsinki.
Cell Cycle Analyses
Analysis of the distribution of different compartments of BM
cells along the G0/G1 and S plus G2/M cell cycle phases (PI) was
performed immediately after samples were obtained using triple-
stainings for nuclear DNA and two cell surface markers. Briefly,
whole BM samples –cell concentration adjusted with phosphate
buffered saline containing 0.5% bovine serum albumin (PBS/BSA;
pH = 7.4) to 106 cells in 100 mL/tube- were incubated in two
separate aliquots for 10 min in the dark at room temperature (RT)
with saturating amounts of the following combinations of
fluorescein isothiocyanate (FITC)2/phycoerythrin (PE)-conjugat-
ed monoclonal antibodies (MAb) purchased from Becton Dick-
inson Biosciences (BD, San Jose, CA, USA): CD45/CD34 and
CD11b/CD13. In order to control for unspecific binding of
antibodies mature lymphocytes and neutrophils were used as an
internal reference. [21] After lysing non-NRBC, nucleated cells
Table 2. Proliferation index (percentage of S+G2M cells) of different compartments of bone marrow (BM) cells in MDS patients
grouped according to the World Health Organization (WHO) classification and the International Prognostic Scoring System (IPSS).
BM cell compartment Proliferation index of BM cell populations
WHO Subtype (n=106)
RA (N=10) RCMD (N=38) RAEB-1 (N=20) RAEB-2 (N=30) MD/MPN (N=8) P-value
Whole BM 13%{{ (6–27%) 9%{{ (2–21%) 9.5%{{ (3–22%) 8% (3–21%) 9.5%{ (4–14%) 0.01
Non-lymphoid CD34+ precursors 21%{{ (8–36) 17% (3–28%) 13.5% (2–30%) 7%{{ (0.6–24%) 18% (4–26%) ,0.001
Maturing neutrophils 8%{{ (6–26%) 6% (2–13%) 7%{{ (2–18%) 7%{{ (2–17%) 9%{{ (4–11%) 0.001
CD13hi/CD11b2 cells 21% (19–51%) 19% (7–35%) 18%{ (9–35%) 15%{{ (6–33%) 25% (15–30%) 0.001
CD13lo/int/CD11b2 cells 27%{ (15–46%) 23% (5–35%) 21% (10–39%) 14.5%{{ (6.5–30%) 22% (10–29%) 0.003
CD13lo/int/CD11b+ cells 8%{{ (3–12%) 5%{{ (0.6–14%) 4% (2–14%) 3.5% (0.6–23%) 9%{{ (3–11%) 0.03
CD13hi/CD11b+ cells 1%{{ (0.4–12%) 1%{{ (0.3–7%) 2%{{ (0.3–12%) 2.5%{{ (0.3–7%) 2%{{ (1–3%) ,0.001
Monocytic cells 5% (1.4–9%) 5.5% (0–16%) 1%{{ (0–11%) 2.7%{ (0–6%) 6% (2–13%) 0.05
Nucleated red blood cell
precursors
31% (24–48%) 28.5% (2–44%) 27% (12–42%) 18%{{ (4.5–42%) 29% (16–40%) 0.001
Eosinophils 3% (1–12%) 7% (0–21%) 5.5% (2–17%) 4% (0–14%) 4.5% (0–16%) NS
BM cell compartment IPSS category (n=85)
Low risk (N=21) INT-1 (N=35) INT-2 (N=15) High risk (N=14) P-value
Whole BM 9%{{ (5–27%) 8% (2–22.5%) 11%{{ (3.5–21%) 8% (3–12.5%) 0.007
Non-lymphoid CD34+ precursors 22.5%{{ (4–36%) 13% (2–30%) 12%{{ (0.6–24%) 7%{{ (1–11%) ,0.001
Maturing neutrophils 8%{{ (3–26%) 6% (2–14%) 6.5%{ (2.5–18%) 7%{{ (3.5–12%) 0.005
CD13hi/CD11b2 cells 25% (7–51%) 18%{{ (6–35%) 18%{{ (6–29%) 13%{{ (8–25%) 0.001
CD13lo/int/CD11b2 cells 25%{{ (10–46%) 21% (5–39%) 17%{{ (7–27%) 15% (6.5–30%) 0.005
CD13lo/int/CD11b+ cells 7%{ (2–12%) 5%{{ (0.6–14%) 3.5% (1.5–15.5%) 4% (2–10%) NS
CD13hi/CD11b+ cells 1.5%{{ (0.3–12%) 1%{{ (0.3–7%) 2%{{ (0.3–12%) 3%{{ (0.3–7.5%) ,0.001
Monocytic cells 5% (0–13%) 2%{{ (0–11%) 6% (1–16%) 3.5% (0–5%) NS
Nucleated red blood cell
precursors
29% (16–48%) 28% (2–44%) 27%{ (4.5–39%) 18%{{ (7–42%) 0.007
Eosinophils 4.5% (1–12%) 6% (0–21%) 6% (0–14%) 4% (0–10%) NS
Results expressed as median percentage of S+G2 M cells and range between brackets. RA, refractory anemia; RCMD, refractory cytopenia with multilineage dysplasia;
RAEB, RA with excess of blasts; MD/MPN, myelodysplastic/myeloproliferative neoplasms; INT, intermediate risk; NS, statistically not significantly different.
{, p,0.05 and
{{, p,0.03 vs. normal/reactive BM.
doi:10.1371/journal.pone.0044321.t002
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were washed and resuspended in 0.5 mL PBS/BSA. Then, 3 ml of
DRAQ5TM (Vitro SA, Madrid, Spain) was added to each tube,
another incubation performed for 10 min in the dark (RT) and the
sample aliquots were immediately run in a FACSCanto IITM flow
cytometer (BDB) using the FACSDiva software program (BD). For
each sample aliquot, information about .16105 cells correspond-
ing to the whole BM cellularity was measured and stored. For data
analysis, the INFINICYTTM software program (Cytognos SL,
Salamanca, Spain) was used. The overall percentage of prolifer-
ating cells, including those cells within the S plus G2/M cell cycle
phases (PI), was defined as those cells showing a brighter staining
of DRAQ5 than those included in the G0/G1 peak, as described
elsewhere [22,23].
In every sample, the following cell populations were identified
after excluding dead cells and cell doublets in a sideward light
scatter (SSC) versus DRAQ5-fluorescence area and a DRAQ5-
fluorescence area versus DRAQ5-fluorescence width bivariate dot
plot, respectively: total CD34+ HPC (CD45lo CD34+ events),
CD34+ non-lymphoid (e.g.: myeloid) HPC (SSCint CD34+),
CD34+ lymphoid HPC (SSClo CD34+ cells), nucleated red cell
precursors (SSClo/very2lo CD452 events), monocytic cells (SSCint
CD45int/hi CD11bhi CD13hi cells), eosinophils (SSChi autofluor-
escent cells), mature lymphocytes (CD45hi SSClo) and maturing
neutrophils (CD45lo SSCint/hi); in addition, maturing neutrophils
were further subdivided into four maturation-associated cell
subsets, as previously described: [24] CD13hi CD11b2, CD13lo/
int CD11b2, CD13lo/int CD11b+ and CD13hi CD11b+ neutrophil
precursors. The specific immunophenotypic characteristics of
mature lymphocytes were taken as a standard to define the
relative position of the different compartments of BM precursors in
a CD45 versus SSC bivariate dot plot. For each of the above listed
cell populations, the distribution along the G0/G1 and S plus G2/M
cell cycle phases (proliferation index) was calculated, as described
above.
Conventional Karyotyping, Fluorescence in situ
Hybridization (FISH) and HUMARA Studies
Cytogenetic analysis of BM samples was performed according to
standard procedures [25] and interpreted using the International
System for Cytogenetic Nomenclature criteria [26]. In addition,
multicolor interphase FISH (iFISH) [27] was systematically
performed for the detection of the most frequent recurrent
cytogenetic abnormalities in MDS, using the following chromo-
somal probes (all purchased from Vysis Inc, Downers Grove, IL,
USA): 1) LSI D5S23, D5S71 Spectrum Green (SG)/LSI EGFR
Spectrum Orange (SO) probe combination for chromosome 5; 2)
LSI D7S486 (7q31) SO/CEP 7 SG probes for chromosome 7; 3)
CEP 8 (D8Z2) SO/CEP Y (DYZ1) SG probes for chromosomes 8
and Y, respectively, and; 4) LSI D20S108 (20q12) SO probe for
chromosome 20. Investigation of the pattern of inactivation of
chromosome X was analyzed in FACS-purified (FACSAria, BDB)
(purity$97%) maturing neutrophils, monocytic cells, NRBC,
CD34+ HPC and mature lymphocytes, as previously reported.
[28].
Statistical Methods
For continuous variables, mean values and standard deviation
(SD), median and range were calculated using the SPSS software
(SPSS 10.0, Chicago, IL); for categorical variables, frequencies
were used (SPSS software). Parametric vs. non-parametric data
distribution was assessed by the Kolmogorov-Smirnov (K-S) test.
For categorical and continuous variables, comparisons between
two or more groups were made using the x2, and either the
Student T (for parametric data) or the Mann-Whitney U and the
Kruskal-Wallis tests (for non-parametric data), respectively.
Receiver operating characteristic (ROC) curves were applied for
the definition of PI cut-off values for association with e.g.
cytopenias and survival. Survival curves were plotted according
to the method of Kaplan and Meier [29] and compared by the log-
Table 3. Proliferation index (percentage of S+G2M cells) of different BM cell compartments in normal/reactive BM (n = 94) and
MDS patients (n = 106) with normal/favourable (n = 83) versus intermediate/poor (n = 23) cytogenetics.
Bone marrow cell subsets MDS
Normal/reactive bone marrow Normal/favourable cytogenetics Intermediate/poor cytogenetics
(n = 94) (n = 83) (n = 23)
Whole BM 7% (1–17.5%) 9%** (2–27%) 9%** (3–22%)
Non-lymphoid CD34+ precursors 15% (6–28%) 14% (0.6–36%) 8%**{{ (1–30%)
Maturing neutrophils 5% (0.5–12%) 7%** (2–26%) 6.5%** (3.5–18%)
CD13hi/CD11b2 cells 21% (4–37%) 19%* (6–51%) 18%** (7–50%)
CD13lo/int/CD11b2 cells 21% (12–36%) 22% (5–46%) 20% (6.5–41%)
CD13lo/int/CD11b+ cells 4% (0.8–12%) 5%** (0.6–16%) 4% (2–23%)
CD13hi/CD11b+ cells 0.5% (0.1–4%) 2%** (0.3–12%) 3%**{{ (0.4–12%)
Monocytic cells 4.5% (0.1–21%) 3.5% (0–11%) 2.5% (0–16%)
Nucleated red blood cell precursors 28% (11–45%) 28% (2–48%) 22%**{{ (4–39%)
Eosinophils 4% (0–13%) 6.5%** (0–21%) 5.5% (0–17%)
Mature lymphocytes 0.060.0% 0.060.0% 0.060.0%
Results expressed as median percentage of cells and range between brackets.
*, p,0.05 and
**, p,0.03 vs. normal/reactive BM; and;
{{, p,0.03 vs. normal/favourable karyotype. Normal/favourable cytogenetics includes cases with a normal karyotype, -Y, del(5q) or isolated del(7q); poor cytogenetics
includes cases with complex ($3 chromosomal abnormalities) karyotypes and alterations of chromosome 7, except isolated del(7q), and; intermediate cytogenetics:
other karyotypic abnormalities.
doi:10.1371/journal.pone.0044321.t003
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rank test. Based on those variables showing a significant effect on
overall survival in the univariate analysis, a multivariate Cox
proportional-hazards model was constructed with those parame-
ters showing independent predictive value; inclusion in the final
model was determined by a backward stepwise approach. P values
,0.05 were considered to be associated with statistical signif-
icance.
Results
Proliferation of Hematopoietic Cells in Normal/reactive
BM
We have recently shown that similar PI are found in normal vs.
reactive BM [8], as confirmed here (Table 1) for the overall BM
cellularity and the distinct compartments of maturing hematopoi-
etic cells, except for non-lymphoid (myeloid plus immature)
CD34+ HPC (1664% vs. 1465%, p = 0.01) and monocytic cells
(4.664.5% vs. 663.5%, p = 0.03). Therefore, from now on normal
and reactive BM samples will be considered together (n = 94) for
further evaluation of potential alterations in the PI of BM cells in
MDS.
Overall Proliferation of Hematopoietic Cells in MDS vs
Normal/reactive and AML BM
Overall, significantly increased numbers of S+G2 M phase cells
(PI) were detected in whole BM of MDS patients vs. controls
(median PI of 9% vs. 7%, p,0.001). Such increased proliferation
was due to increased PI of maturing neutrophils (p,0.001) at the
expense of the more mature CD11b+ granulocytes (p#0.002)
(Table 1). By contrast, both non-lymphoid CD34+ HPC and the
more immature CD13hi/CD11b2 neutrophil precursors showed
significantly lower PI in MDS vs. normal/reactive BM (p#0.05)
(Table 1).
In turn, AML NOS cases showed an overall BM proliferation
rate similar to normal/reactive BM, but significantly lower than
that of MDS (PI of 7% vs. 9%, respectively; p = 0.008) (Table 1). In
detail, AML showed a pronounced decrease of the PI of non-
lymphoid CD34+ cells (p,0.001) and NRBC (p#0.01) vs. both
normal/reactive BM and MDS. In turn, a marked increased
proliferation was detected in AML patients among the CD13lo/int/
CD11b+ and CD13hi/CD11b+ subsets of maturing neutrophils vs.
normal/reactive BM (p#0.001), the latter subset also showing an
increased PI vs. MDS (p = 0.007) (Table 1).
Proliferation of BM Cells in Different Diagnostic Subtypes
of MDS
Despite the increased overall BM proliferation detected in MDS
vs. both AML and normal/reactive BM, distinct proliferation
profiles were observed for the different BM cell compartments
among the diagnostic and prognostic subgroups of MDS (Table 2),
except for RA and RCMD patients with vs. without ring
sideroblasts; therefore, these two WHO subtypes of MDS were
grouped together.
Overall, the highest BM PI was observed among RA and low-
risk MDS patients (13% and 9% vs. 7%, p#0.006). Such increased
proliferation was associated with a greater PI of non-lymphoid
CD34+ precursors in both subgroups of early MDS patients
(p#0.006). However, the PI of these precursors showed a trend to
decline in high-risk MDS, reaching minimal proliferation values in
RAEB-2, intermediate-2, high-risk IPSS MDS and AML patients
(p#0.01 vs. normal BM, RA and low-risk MDS) (Table 2).
Similarly, despite a significantly enhanced proliferation of
maturing BM neutrophils was found in all diagnostic categories
of MDS but RCMD (p#0.01), as well as in AML (p#0.02), a
more detailed analysis of the neutrophil maturation stages
(Table 2), revealed again significantly different proliferation
profiles in early vs. advanced MDS/AML, particularly among
the more immature neutrophil precursors. Thus, all MDS
diagnostic categories showed a significantly increased PI for the
more mature CD13hi/CD11b+ and/or CD13lo/int/CD11b+ neu-
trophil subsets (p#0.04); by contrast, although a similarly
increased (p#0.03) or stable PI was detected among immature
CD11b2 neutrophil precursors from RA and low-risk IPSS MDS,
decreased PI (vs. normal/reactive BM) were found for these cells
(CD13hi/CD11b2 myeloblasts) in RAEB-1 and both intermedi-
ate-1- and high-risk IPSS MDS (p#0.04) as well as (CD13hi/
Table 4. Relationship between the degree of proliferation of non-lymphoid CD34+ and nucleated red blood cells from patients
with myelodysplastic syndromes (MDS) and other haematological and biochemical characteristics of the disease.
MDS patient subgroups PI of non-lymphoid CD34
+ precursors PI of nucleated red blood cells
PI $10% PI ,10% P-value PI $24% PI ,24% P-value
N. of cytopenias ($2) (n = 84) 29/52 (56%) 27/32 (84%) 0.007 28/49 (57%) 28/35 (80%) 0.02
Anemia (,100 g haemoglobin/L) (n = 83) 28/52 (54%) 26/31 (84%) 0.006 26/49 (53%) 28/34 (82%) 0.006
Thrombocytopenia (,1006109 platelets/L)
(n = 84)
19/52 (36.5%) 22/32 (70%) 0.004 17/49 (35%) 24/35 (70%) 0.002
Leukopenia (,56109 leukocytes/L) (n = 84) 26/52 (50%) 18/32 (56%) NS 26/49 (53%) 18/35 (51%) NS
Increased LDH (.400 IU/L) (n = 72) 6/43 (14%) 13/29 (45%) 0.004 7/40 (18%) 12/32 (38%) 0.05
Neutropenia (,1.86109 neutrophils/L) (n = 64) 19/37 (52%) 18/27 (67%) NS 17/35 (48.5%) 20/29 (70%) NS
Transfusion dependency (n = 65) 16/40 (40%) 21/25 (84%) ,0.001 12/36 (33%) 25/29 (86%) ,0.001
Intermediate/poor cytogenetics (n = 98) 6/63 (10%) 16/35 (46%) ,0.001 9/60 (15%) 13/38 (34%) 0.02
Evolution to AL (n = 77) 6/48 (12%) 11/29 (38%) 0.009 5/46 (10%) 12/31 (40%) 0.004
Results expressed as number of cases from all MDS patients analyzed and percentage between brackets.
PI, proliferation index;
LDH, lactate dehydrogenase;
AL, acute leukemia;
NS, statistically not significantly different.
doi:10.1371/journal.pone.0044321.t004
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CD11b2 myeloblasts and CD13lo/int/CD11b2 promyelocytes) in
RAEB-2 and intermediate-2 IPSS MDS cases (p#0.02). Of note,
BM cells from MD/MPN patients showed proliferation patterns
similar to those of early/low-risk MDS cases, while in AML they
resembled those of advanced/high-risk MDS patients (Table 2).
In addition, altered proliferation patterns were also observed
among BM NRBC from both MDS and AML patients: the PI of
NRBC tended to increase in RA patients (p.0.05 vs. normal/
reactive BM) while it significantly declined in intermediate-2-
(p = 0.05), RAEB-2 (p,0.001), high-risk MDS (p,0.001), and in
AML (p,0.001) (Tables 1 and 2). In turn, the cell cycle
distribution of monocytic cells remained at normal/reactive levels
in early MDS and AML, while abnormally lower PI were observed
in RAEB-1, intermediate-1-risk and RAEB-2 patients (p#0.05 vs.
normal/reactive BM); conversely, a tendency towards increased
monocytic proliferation was detected in MD/MPN (p.0.05).
No significant differences were noted in the PI of other BM cell
compartments analyzed (e.g.: B-cell committed CD34+ precursors)
neither in MDS nor in AML; mature lymphocytes systematically
corresponded to resting cells in all groups analyzed.
Although variable results were observed for individual cases,
follow-up studies performed in a group of 11 MDS patients
showed a tendency towards decreased PI of non-lymphoid CD34+
cells –from 5% (0–17%) to 0.9% (0–14%); p = 0.06-, CD11b2
neutrophil precursors –from 30% (8–38%) to 16% (4–28%);
p = 0.02- and NRBC –from 28% (9–32%) to 19% (7–30%);
p = 0.05- vs. those found at diagnosis; such tendency was observed
not only among cases which showed more advanced disease but
also among cases which had the same WHO diagnosis after
follow-up (n = 5, data not shown). The only exception correspond-
ed to those two cases who achieved remission, in which the PI of
the different compartments of BM cells returned to normal BM
values: PI of non-lymphoid CD34+ cells, CD11b2 neutrophil
precursors and NRBC of 6% (3–9%), 11.5% (8–15%) and 19%
(13–25%) vs. 15% (14–16%), 32.5% (22–43%) and 27% (26–
28%), respectively.
Cell Cycle Distribution of BM Cells in Different
Cytogenetic Subgroups of MDS
MDS cases with normal/favourable karyotypes as well as cases
with isolated del(7q) showed similar proliferation profiles consisting
of an enhanced BM proliferation (p = 0.007) due to an increased
PI of the more mature neutrophils (p = 0.01) in the absence of
altered cell cycle profiles among non-lymphoid CD34+ and NRBC
precursors (Table 3). Conversely, patients with intermediate/poor
cytogenetics had decreased PI of non-lymphoid CD34+ and
NRBC vs. both normal/reactive BM (p#0.002) and MDS cases
with normal/favourable cytogenetics (p = 0.01) (Table 3).
Relationship between the PI of BM Cell Compartments in
MDS and other Features of the Disease
Upon grouping MDS patients according to the PI of BM cells
(Table 4), a clear association was observed between a lower PI of
non-lymphoid CD34+ precursors (PI: ,10% vs $10%) and other
relevant features of the disease such as anemia (p = 0.006),
thrombocytopenia (p = 0.004) and multiple ($2) cytopenias
(p = 0.007), transfusion dependency (p,0.001), increased serum
LDH (p = 0.004), intermediate/poor cytogenetics (p,0.001) and
transformation to acute leukemia (AL) (p = 0.009). Likewise, low
NRBC PI (,24% vs $24%) were also associated with a greater
frequency of $2 cytopenias (p = 0.02), anemia (p = 0.006),
thrombocytopenia (p = 0.002), transfusion dependency
(p,0.001), increased LDH (p = 0.05), intermediate/poor karyo-
types (p = 0.02) and transformation to AL (p = 0.004) (Table 4).
Interestingly, a low PI (,12.5% and ,11.7%) of non-lymphoid
CD34+ cells could predict with a great efficiency among MDS
cases for the presence of anemia and thrombocytopenia,
respectively (sensitivity of 63% and specificity of 80% in both
cases; p#0.02); likewise, a PI of NRBC ,24.5% also predicted for
anemia with a high specificity (sensitivity of 49%, specificity of
80%; p = 0.05), while a low PI of CD13hi/CD11b2 maturing
neutrophils efficiently identified patients with neutropenia (sensi-
tivity of 65%, specificity of 70%; p = 0.03).
Impact of Cell Proliferation on the Outcome of MDS
From the prognostic point of view, a significantly shorter
median overall survival (OS) was observed among MDS cases
which displayed lower percentages of proliferating non-lymphoid
CD34+ precursors (p = 0.005) and NRBC (p,0.001), thrombocy-
topenia (p,0.001), $2 cytopenias (p = 0.02), increased serum
LDH (p = 0.004), transfusion dependency (p = 0.01) and higher
IPSS and WPSS scores (p,0.001). In turn, a lower percentage of
proliferating non-lymphoid CD34+ precursors (p = 0.001) and
NRBC (p,0.001), together with the presence of thrombocytope-
nia (p = 0.001), $2 cytopenias (p = 0.01), transfusion dependency
(p = 0.04) and higher IPSS or WPSS scores (p#0.02), were also
associated with a greater risk of transformation to AL (Figure 1
and Table 5). Most interestingly, low- and intermediate-1 risk
MDS patients with abnormally lower PI of non-lymphoid CD34+
precursors and NRBC showed a significantly lower median OS -
16 vs 132 (p = 0.03) and 15 vs 132 months (p = 0.001), respectively-
and a higher risk of transformation to AL –median of 37 vs 135
(p = 0.005) and of 37 vs 135 months (p = 0.002), respectively-
(Figure 2). Meanwhile, intermediate-2 and high-risk MDS with
low PI of NRBC displayed significantly shorter survival rates
(median OS of 9 vs 22 months, respectively; p = 0.03) (Figure 2).
Multivariate analysis of prognostic factors (Table 5) showed that
the combination of the PI of NRBC –hazard ratio (HR) of 3.7;
95% CI of 2–7; p = 0.005) and thrombocytopenia (HR of 2.7; 95%
CI of 1.3–6; p = 0.008), were the only two parameters showing
independent predictive value for OS in MDS, while the PI of
NRBC was the most informative independent predictor for
transformation of MDS to AL both as categorical (HR of 12.3;
95% CI of 1.5–99.5; p = 0.01), and as a continuous variable
(p = 0.01).
Discussion
Prediction of outcome in MDS by conventional prognostic
stratification models remains only partially successful. This is
mainly due to the heterogeneous clinical behaviour and response
to treatment observed, particularly among low-risk cases. Because
of this, an increasing interest exists on the identification of new
prognostic factors that could provide already at diagnosis, a more
Figure 1. Impact of currently used prognostic classifications and other disease features on overall survival and risk of
transformation to acute leukemia (AL) of patients with myelodysplastic syndromes (MDS; n=106). Overall survival (left column) and
progression-free survival (transformation to AL; right column) curves are plotted for patients with MDS grouped according to the International
Prognostic Scoring System (IPSS; row A), the World Health Organization-based Scoring System (WPSS; row B), the number of peripheral blood
platelets at diagnosis (row C), the presence of multiple cytopenias (row D), transfusion dependency (row E), and serum LDH levels (row F).
doi:10.1371/journal.pone.0044321.g001
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dynamic assessment of the behaviour of the disease and contribute
to refine the currently used classifications to improve the
management of individual patients [6,7]. Although several
parameters related to BM failure (e.g.: hemoglobin levels,
transfusion needs, number of cytopenias) are significantly associ-
ated with the prognosis of the disease, and evidence exists about
the potential involvement of cell proliferation in the pathogenesis
of MDS, to the best of our knowledge, no study has been reported
so far in which the proliferation profile of different compartments
of BM cells is analyzed in MDS, and correlated with disease
outcome.
Here, we investigated for the first time the proliferation rate of
different compartments of BM hematopoietic cells in MDS vs.
both normal/reactive BM and AML. Overall, an increased
proliferation of BM cells was found in MDS vs. the other two
groups, in line with previous observations [30,31]. Specific analysis
of the PI of distinct BM cell compartments revealed that such
increased proliferation was mainly due to a higher PI of CD11b+
maturing neutrophils which could be viewed as an attempt to
compensate for the need to produce mature neutrophils, required
to maintain homeostatic levels of these cells in peripheral blood
(PB). However, more detailed analysis of the PI of these and other
BM cell compartments within the distinct diagnostic and
prognostic subtypes of MDS highlighted the existence of
significantly different proliferation profiles in low- vs. high-risk
cases. Accordingly, early/low-risk MDS patients (RA and low-risk
IPSS MDS) typically showed an overall increased proliferation of
BM cells at the expenses of CD34+ non-lymphoid (myeloid plus
uncommitted) precursors, maturing neutrophils and NRBC;
conversely, advanced/high-risk patients showed progressive col-
lapse of proliferation of these cell compartments, except for the
more mature CD11b+ neutrophil-lineage cells, similarly to what
was found in AML. These observations are in line with the more
severe and numerous cytopenias found among the latter group of
MDS patients, as well as with the hypermethylated status of cell
cycle controlling genes (e.g.: p15INK4b, CDKN2B) reported to be
associated with an enhanced hematopoiesis and neutrophil
differentiation among specific subtypes of low-risk MDS (e.g.:
RA with ringed sideroblasts) [32,33,34]. These differences in the
proliferation rate of early/low-risk vs. advanced/high-risk MDS
patients may be also related to overexpression of cell cycle-
associated genes in precursor cells from early MDS (e.g.: cyclins B,
C, D1 and D2), which would be downregulated or suppressed in
advanced disease [14,31,35]. Similar to reactive BM, the higher
proliferation of the more mature neutrophil lineage cells observed
in MDS probably reflects an attempt to counteract neutropenia
[8] by abnormally enhancing the proliferation capability of more
differentiated cells [36]. In turn, the progressive collapse of cell
proliferation in advanced/high-risk MDS cases could directly or
indirectly be related to the accumulation of secondary genetic
lesions and/or a progressively impaired BM stroma and cytokine
production/response by the dysplastic hematopoietic BM precur-
sors. In line with these observations, we have also recently found
increased numbers of early CD34+/CyMPO+ neutrophil and
CD34+/CD36+/CD123lo erythroid precursors within the BM
CD34+ HPC from early/low-risk MDS, while in advanced/high-
risk MDS neutrophil and erythroid differentiation of CD34+ cells
typically appeared to be blocked [37]. Of note, similar patterns of
evolution were observed when analysis of cell proliferation was
performed in paired diagnostic and follow-up samples from a
subgroup of 11 MDS patients.
Altogether, these findings suggest that an increased proliferation
of neutrophil and erythroid precursors, already detectable among
CD34+ non-lymphoid (uncommitted plus myeloid) HPC in the
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early stages of the disease, could reflect an attempt of the BM to
maintain peripheral counts of mature red cells and neutrophils,
required for the subject to remain alive. Conversely, the impaired
decreased proliferation of early myeloid precursors, particularly of
the neutrophil and erythroid lineage, could represent an early
event during progression of early/low-risk to advanced/high-risk
MDS and a surrogate marker for a progressively increased risk of
transformation to AL, further leading to the worsening of
cytopenias observed in advanced disease. The acquired secondary
genetic alterations and hypermethylation patterns observed among
CD34+ and maturing BM cells from advanced MDS [32,36]
might further lead to abnormal expression of genes associated with
basic cell functions (e.g.: Ankaryn 1 and Tropomodulin in the
erythroid lineage) [38], consequently contributing to a gradual
defective capacity for multilineage proliferation and differentiation
of BM precursors [24,37]. Overall, our findings point to a
potentially altered response of advanced MDS patients to cell cycle
and apoptotic mediators, specially among non-lymphoid (uncom-
mitted plus myeloid) CD34+, NRBC and immature neutrophil
precursors, whereas the more mature neutrophils might retain
residual susceptibility to such proliferation stimuli. Noteworthy,
MD/MPN patients showed a BM proliferation profile similar to
that of early/low-risk cases, except for a slightly increased PI
among monocytic precursors. Overexpression of cell-cycle pro-
teins (e.g.: cyclin D1) specifically found among these patients could
contribute to this unique profile [31]. Of note, our results could be
viewed as apparently controversial since they show a progressively
decreased cell proliferation of CD34+ cells in association with a
higher accumulation of blast cells from low- to high-risk MDS and
AML. However, they probably indicate that despite being highly
proliferative, blast cells from low-risk MDS still retain their
capacity to differentiate into more mature cells and therefore they
do not accumulate at this stage. Conversely, high-risk MDS blast
cells lose their ability to differentiate into more mature cells, such
maturation blockade being associated with a numerical expansion
of cells with increased survival and decreased apoptotic signalling,
which most probably reflects both a decreased ability to maturate
and also to proliferate, as both cell functions are intimately linked
during hematopoiesis.
Based on all the above it could be expected that the impaired
proliferation of distinct BM cell compartments in MDS could also
be associated with individual prognostic factors, as well as with
patient outcome. In detail, a significant association was specifically
found between a low PI of non-lymphoid CD34+ precursors and
NRBC and other adverse features of the disease (e.g.: higher
number of cytopenias, anemia, thrombocytopenia, increased
serum LDH, transfusion requirements and intermediate/poor
cytogenetics) as well as with a worse disease outcome -shorter OS
and progression to AL free survival (PFS)-. Interestingly, the
impact of the degree of impairment of the proliferation of these
two subsets of BM precursors in the outcome of MDS patients was
retained when early/low-risk and advanced/high-risk MDS
patients were separately considered. Even more, multivariate
analysis of prognostic factors showed that a decreased PI of NRBC
was the most powerful independent prognostic factor for both OS
and acute leukemia PFS of MDS patients.
Altogether, these results suggest that assessment of the PI of
NRBC, and potentially also of other compartments of BM
precursors (e.g.: myeloid CD34+ HPC), could significantly
contribute to a better management of MDS patients, potentially
also during monitoring of the effects of new drugs and
therapeutical strategies.
In summary, our results show the existence of altered
proliferation profiles in the BM of MDS patients which are
associated with unique but different patterns in early/low-risk vs.
advanced/high-risk MDS. From the prognostic point of view, an
abnormally low PI of non-lymphoid CD34+ cells and NRBC were
both associated with a significantly longer OS and decreased risk
of transformation to AL, even when early/low-risk and advanced/
high-risk MDS patients were separately considered, the PI of
NRBC emerging as an independent prognostic factor for both OS
and PFS in MDS.
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